 | The pharmaceutical industry is one of the fastest growing sectors in Indian economy. Visiongain predicts that market for pharmaceuticals in India has strong potential for increased growth from 2008 right through to 2023. The industry’s leading Indian Pharma report contains unique market-based research, including detailed interviews with key opinion leaders based in India and abroad. Importantly, the report forecasts the overall Indian pharmaceutical market from 2008 to 2023, as well as that of many important market segments. Other key metrics are also included throughout the report. This is your opportunity to gain critical insight into the potential and inner workings of one of the world’s most important healthcare markets from the present onwards. |
|
| In 2006, Pfizer’s Lipitor (atorvastatin) generated global revenues of $13.6bn, making it the best selling drug in pharmaceutical history. The blockbuster medicine has single-handedly driven the overall revenue margins of the cardiovascular segment, as this area continues to dominate the pharmaceutical market. Despite the maturing status of Lipitor, the drug has repeatedly maintained steady growth over the past 5 years, crowding out the yearly revenues of other lipid-regulating blockbuster drugs: Merck& Co’s Zocor and Zetia, Astrazeneca’s Crestor, Abbott’s Tricor and Bristol Myers Squibb’s Pravacol. |
|
| This brand new report examines the prospects for the growth of pharmaceutical revenues in China. Visiongain predicts that total pharmaceutical revenues in China will increase from approximately $12bn in 2007 to over $30bn in 2013. This is a considerable increase, one that will represent a near tripling of total sales over six years. Strong growth will continue well beyond that period, as this report shows and explains. |
|
| In 2007, blood diseases cost the US’s economy $114bn. In 2004, a reported 232,000 deaths in the US were due to anaemia, myeloproliferative and myelodysplastic disorders, bleeding disorders, white blood cell disorders and thrombosis collectively. From oxygen delivery to immunological defence to clotting, blood has vital physiological functions, and clear, expensive treatments. This brand new blood diseases treatments report breaks down therapies into four main groups:• Antithrombotics• Anti-anaemics• Clotting Factors• Others |
|
| Which current or future therapies will drive the sleep disorders market from 2008 to 2018?What is the patient identification rate for each of the therapeutic areas?What is the present state of the disease awareness?What R&D opportunities exist for ‘new comers’?Which key companies are involved in the market?This report will tell you. The report focuses on the market for following sleep disorders:• Insomnia• Restless legs syndrome (RLS) • Narcolepsy and • Obstructive Sleep Apnoea / Hypopnea Syndrome (OSAHS) |
|
| The generic industry is a fast evolving market; with significant lucrative opportunities. The generic market is structurally set to experience high growth potential. That wave is partly driven by cost-containment in several national healthcare sectors and partly by the need for governments to promote the use of generic products over high-priced originator products without compromising quality.In 2006, the global generics market attained strong revenues of approximately $65bn, up by 12% in comparison with $58bn in 2005. However, during the same period, the Top Ten leading generic suppliers generated total revenues of $27.9bn, up by a growth rate of 34%. The Top Five Companies within that sector experienced significant revenues, with market growth largely driven by significant commercial activities, key Mergers and Acquisition (M&A) and launch of new product in the leading markets. |
|
| This brand new market analysis by visiongain examines the prospects for antibacterial drugs from 2008 to 2013, including sales forecasts for leading pharmaceutical products. The antibacterial market is large in terms of disease area as well as the different drug classes. However, this market is entering into a crucial period with many key products losing patent protection, facing heavy generic competition. In the light of this, including other factors, visiongain predicts this market to decline in revenues – but which products will suffer most? How can you fight this generic competition? The antibacterial drug market generated revenues of $30274m in 2006 – but what will it be in 2013? |
|
| This brand new report examines the forthcoming prospects for respiratory drugs over the next 5 year. With in-depth sales forecasts for leading pharmaceutical products, the report has been produced to inform you of future developments and strategies. The respiratory market generated revenues of $30503m in 2006, but what will it be in 2013? Which year the market will reach its peak? |
|
| The total antipsychotics market revenue in 2006 was $18.1bn. Visiongain predicts that total revenues in the antipsychotics market will peak to $18.6bn by 2007. But what will it be in 2012? This report will tell you. This in-depth market analysis examines prospects for antipsychotic drugs right through to 2012, including sales forecasts for leading products. The antipsychotics market will face decreasing growth throughout the forecast period, due to the patent expiry of leading blockbuster drugs. Safety concerns over the current antipsychotics along with high prices, will also contribute to decreased growth in this market. |
|
| The market for Erectile Dysfunction (ED) drugs is growing fast with a CAGR of 4.9% for the period 2006-2012. The ED market contains three leading drugs Viagra, Levitra and Cialis. Viagra, already a blockbuster drug, is the most popular and recognised brand on the market. Furthermore, high revenues are predicted by visiongain for the top three ED drugs, with Cialis reaching blockbuster status by 2007. This detailed report also highlights pipeline developments and important contemporary issues, especially commercial drivers and restraints. The purpose of this market analysis by visiongain is to examine prospects for Erectile Dysfunction (ED) drugs from 2007-2022, including sales forecasts for leading pharmaceutical products. |
|
| Visiongain predict that the current phase I to IV clinical testing process will eventually be selectively or wholly replaced by a system known as “in-life” testing or “live” licensing. Those proposals involve cumulative testing of the drug throughout its lifecycle. The industry would continually test drugs with smaller, more focused clinical trials. If a trial shows efficacy and safety, a live license would be given, allowing the company to market the drug in a limited manner. Already, the FDA and the EMEA have shown favourable interest in such developments - amongst other amendments to current practice. |
|
| Migraine is a serious neurological disorder characterised by recurrent headaches, varying in severity and frequency. Accounting for the loss of over 100 million working days in the US alone, the economic cost and social impact of migraine is significant. Furthermore, the people most susceptible to migraine are those within their most productive years (22-55), causing both personal and professional disruptions and a significant burden on healthcare services. |
|
| Most skin disorders are not fatal but most people are affected globally. The revenue of dermatological market in 2006 was $16bn, which is a 5.1% when compared with 2003. The common skin disorders include acne, dermatitis, psoriasis, rosacea, urticaria and hair loss. Due to the aesthetic awareness increases in Western countries, botulinum toxin and other cosmetic treatments become more and more popular. |
|
| Alzheimers disease (AD) is the third leading cause of death in recent times and with an unprecedented patient potential, this disease area attracts awareness from a broad base of stake holders. With the grey population being the single most influencial factor in driving the economic growth within this sector, Visiongain believes the real market of the AD industry still remains untapped. |
|
| The World Health Organization (WHO) estimates that over 2.5 million people globally suffer from Multiple Sclerosis (MS). With the present global population growing to an unprecedented height of 6.5 billion in 2005 and growth rate anticipated to reach 7.6 billion by 2020, the prevalence and onset of MS in children and particularly adults is expected to rise exponentially. |
|
| The market for hypertensives - led by the angiotensin II antagonists - is one of the largest and most profitable in the global pharmaceutical market, with total anti-hypertensive sales of $36600m in 2006. Hypertension, or high blood pressure, is a worldwide epidemic: by 2025 visiongain predict that worldwide there will be more than 1.5 billion sufferers of this disease. Modern lifestyles, such as poor diet and lack of exercise, are the main contributory factors to elevated blood pressure. Consequently, the incidence and prevalence of hypertension are increasing rapidly in both developed and developing countries. |
|
| Diabetes affects approximately 246 million people worldwide and this number is increasing. The IDF predict 380 million diabetics by 2025. The Global Diabetes drug treatment market was valued at over $21 billion in 2006 and the market is still expanding rapidly due to the high prevalence of diabetes and lifestyle changes. You cannot afford to ignore this market. To ignore this report when your competitors are reading it, would be a mistake. I urge you to read this report today. |
|
| The global pain pharmaceutical market is set to become a serious growth area experiencing a compound annual growth rate of 4.56% to 2012. Visiongain's latest report, "The Global Pain Pharmaceutical Market 2007-2022 ", explains just how this market will experience growth over the medium term future. The report also highlights forecast for 2022, so that you and your company can make longer term plans. |
|
| - Do you know what the next major blockbuster will be?- In the year 2000, when visiongain first produced their Blockbuster Drug market report there were 55 blockbuster drugs – now there are over 100. |
|
| Visiongain believe that the market for non-opioid drugs is the fastest growing segments in pain management with a CAGR of 8.12% for the period 2006-2012. The brand new report entitled “The Global Non-Opioid Market in Pain Management” has highlighted a number of innovative pipeline developments that are set to shape the industry over the medium term. |
|
 | Amyotrophic lateral sclerosis (ALS) also known as Lou Gehrig's disease in the US, Maladie de Charcot in France and Motor Neuron Disease (MND) in the UK is a progressive neuromuscular disease characterised by the progressive degeneration of motor nerve cell in the brain (upper motor neurons) and spinal cord (lower motor). To date there is no cure for ALS. Present day medical management of the disease through the combinatorial use of medications and advancements in state-of-art technological devices for nutrition and breathing, have markedly increased the survival rate of ALS sufferers. |
|
 | Increasingly the large pharmaceutical companies are pumping money and ambition into the DNA/RNA therapy market. Whether its through forming collaboration/licensing agreements, or acquiring smaller companies they can see the financial opportunities. In particular the large pharmaceutical companies Pfizer, sanofi-aventis, Eli Lilly & Company and Merck & Co all have substantial investment in the RNA/DNA therapy products market. With Merck & Co in particularly showing its faith in the future potential of this market by taking the gamble of acquiring the specialist RNAi company Sirna, towards the end of 2006. |
|
 | "By 2010, almost 50 percent of children in North America and 38 percent of those in the European Union will be overweight, researcher has found". For pharmaceutical companies looking to target growing successful markets, the anti-obesity drug treatment market offers unique opportunities. |
|
 | Cigarette smoking is the most important source of preventable and premature morbidity worldwide. Currently, the number of smokers across the globe is estimated at 1.3 billion. Political moves are leading to national bans of smoking in public places, with the long-term aim to reduce the cost to the health sector. But what will be the short-term spending on smoking cessation therapies? |
|
|
 | Marinol®, Cesamet®, Sativex ® and Rimonabant are all commercially-marketed cannabinoids. They treat a variety of conditions from weight-loss to pain relief. The introduction of cannabinoids into the pharmaceutical marketplace has begun, and attitudes to the drugs are changing. This increased acceptance will lead to greater market penetration, and the importance of the area will be seen with the first cannabinoid reaching blockbuster status before the end of the decade. |
|
 | With the recent Alzheimer's Association International Conference suggesting a new era of hope for sufferers of the illness, drug trials have shown some enlightening discoveries. |
|
| Gastrointestinal (GI) disorders are set to affect over 250 million people in the seven largest pharma markets, by 2012. As generations of people become more obese and consume increasingly poor diets then so too will the number of people suffering from these disorders rise. |
|
 | "Teva has a robust corporate strategy that should serve it well for years to come, driving strong growth and further innovation. Teva is therefore one of the most exciting and dynamic companies in the global pharmaceutical industry," finds visiongain report.Just some of the recent headlines surrounding Teva:- Court rules against Teva in patent dispute – May 11th - Teva gets tentative ok for generic of Eli Lilly’s Gemzar – May 8th- Teva Announces Approval and Shipment of Generic Omnicef – May 14th- Teva loses Merck generics race to U.S. rival Mylan - May 14th |
|
 | Driven by demographic trends, such as an increasing aged population, the global ophthalmic pharmaceutical market is set to become a serious growth area experiencing a compound annual growth rate of 11.11 per cent to 2012. This report explains just how this market will experience growth over the medium term future. Also do you know what the drivers and restraints of the market are? This report not only reveals these, but also details what strategies can be used to maximize profits from the drivers and restraints. |
|
 | Founded by Indian Scientist Dr Anji Reddy in 1984, the company has developed into a fast-growing international corporation, with headquarters in Hyderabad, Andhra Pradesh, India. During the fiscal year 2006, Dr. Reddy’s was the third-largest Indian pharmaceutical company, with net revenue of $546m. However they have not rested there. Throughout 2007, Dr. Reddy’s has been jostling for leadership among the Indian companies, due to spectacular growth in recent quarters. This company is moving rapidly. Are they a major competitor of yours? Are you partnering with them? Whatever your relationship with the company you need to be fully aware of how they operate and will develop over the next 5 years. |
|
 | The number of blockbusters continues to increase. The number is set to increase to 112 in 2007. Of the products set to receive FDA approval this year and generate blockbuster status on an annual basis, GSK's Cervarix, intended for the prevention of infection and lesions from the two cancer-causing types of HPVs holds great potential. |
|
 | With 4 drugs now in the marketplace (a 100% rise from 2 years ago), the cannabinoid market continues to grow. Attitudes to the drugs are changing ensuring greater market penetration, and the first cannabinoid blockbuster is now a certainty. |
|
 | AMD is the most common cause of vision loss in the developed world for those over 50 years of age. We estimate there are over 20 million cases in the US and Europe. Dry AMD accounts for 90% of cases and has no suitable cure. Wet AMD drug sales will soon see the first blockbuster. Novartis achieved first to market success with their Visudyne drug in 1999. However work from Pfizer selling Macugen and Lucentis from Genentech have seen it sales reduced. These drugs are refered to in the press as ‘miracle drugs’ – saving sight for millions. But issues over prescribing still remain. |
|
 | In a market believed to approach 5 million people in the leading pharma markets, the market for rheumatic anti-inflammatory drugs is both profitable and set to increase due to new launches. The annual revenue to Q3 2006, from the main prescription anti-inflammatory drugs worldwide, including non steroidal anti-inflammatories (NSAIDs), anti-rheumatic corticosteroid combinations and specific anti-rheumatics was in the order of $16bn worldwide. This market cannot be ignored. A life-long disease with no cure, the disease has been targeted greatly by pharma companies with the launch of novel targetted biologic therapies. However this has meant that the market for severe RA has become crowded - but is it saturated? |
|
 | Over 160+ pages dedicated to tissue engineering and stem cell analysis.The market potential of this technology is so huge that revenues may be in excess of $10 billion by 2013. This is a market that you should be part of - NOW!! With a complex regulatory structure still to overcome, yet continued high level investment, many of your competitors are aware of the the commercial opportunities within Tissue Engineering & Stem Cell Technology. |
|
 | With headquarters in Basel, Switzerland, Novartis is recognised as being one of the strongest performing pharmaceutical companies in terms of sales, high revenue growth, acquisitions, breadth of portfolio, product launches and pipeline developments. In 2006 - ten years after its inception - Novartis generated total net sales of $37bn worldwide. |
|
 | The two major problems for biotech drugs are their mode of delivery and relative instability. The majority of delivery methods for biological drugs involve injection, which is not necessarily ideal for most indications. As the biotech sector starts to heat up, the industry has started to look for new ways of delivering these highly successful drugs. |
|
 | 'The Autoimmune Inflammatory Bowel Disease Market Outlook to 2012' is a new report from visiongain providing analysis of the current and future market for IBD drugs across all major indications. Forecasts are given based on new product launches, upcoming patent expiry dates, and ongoing clinical trials to enable you to predict changes in the dynamics of the global IBD market. Autoimmune disease is a multimillion dollar market set to increase as world prevalence rates rise and the population lives longer. Inflammatory bowel disease (IBD) affect millions of people worldwide with 2.8 million currently diagnosed with ulcerative colitis (UC) or Crohn’s disease (CD) in the US alone. The incidence of IBD is rising in developing countries around the world. Currently the global market is estimated at $16bn and this is set to continue to rise. |
|
 | Key questions remain over theranostics. How can your company secure key successes and ideals in personalized medicine - aiming the right drug at the right person and at the right time. Plus with increased FDA regulation, how can we guarantee that that specific drug is safe for that individual. These issues are not going away, but one report can make it alot easier for you and your company. |
|
 | Stem cells are without doubt the most controversial area of science at the moment. The world markets have latched onto the potential offered by stem cells to modern medicine and, as a result, the research is in the public eye on an almost daily basis. Are you fully informed of the market potential of stem cell work? Do you know which companies and research organisations you must work with now? This report tells you.So what is all the controversy about? And what products are we likely to see, in what areas and when, if stem cell work continues at pace? |
|
 | "Lung cancer vaccine to be tested" "New US bill requires cancer vaccine for girls" "Cancer vaccine too expensive".These are just some of the news headlines that have seen the world cancer vaccine market turned on its head. The benefits are unquestionable, the costs of the drugs however may yet see take-up slow. How will this effect your company? This report will tell you. There are two types of cancer vaccines:> Prophylactic cancer vaccines, designed to prevent the development of cancer, they are given to healthy subjects to prevent infection with cancer-causing viruses > Therapeutic cancer vaccines, designed to treat existing cancers, they are given to cancer patients to stimulate the immune system into recognising and destroying their existing cancer |
|
 | The purpose of visiongain’s Developing Markets Series is to examine prospects for the growth of pharmaceutical revenues in the developing economies of Asia, Latin America and Eastern/Central Europe in three linked reports. Central and Eastern European (CEE) Developing Markets for Pharmaceuticals, 2006-2011 – Part 3 of Developing Markets - discusses prospects for the large developing market of Central and Eastern Europe. The other reports discuss Asia and Latin America respectively. Importantly, the growth of pharmaceutical markets in economically developing nations has the potential to offset serious problems currently being experienced by the global industry. The purpose of this visiongain report is to examine the prospects for the growth of pharmaceutical revenues in the developing economies of Central and Eastern Europe, at both regional and national level. |
|
 | The monoclonal market is set to expand dramatically. Ten years ago there were only two monoclonal antibody drugs on the world market, now there are nineteen FDA approved therapies – including six blockbuster drugs. The market in 2005 was worth over $13bn, worldwide, representing an astounding growth of 37% - can you believe it? Well you should and to make sure you capture an increased share of this growth order this report NOW. Biotech pipelines are overflowing with over 160 monoclonal antibody based drugs; the market is thriving! Will the current monoclonal blockbusters continue to grow? What are the hottest projects in the pipeline? What will restrain the market in the future? These are questions you need to know the answers to. |
|
 | The purpose of visiongain’s Developing Markets Series is to examine the prospects for the growth of pharmaceutical revenues in the developing economies of Asia, Latin America and Eastern/Central Europe. Latin American Developing Markets for Pharmaceuticals, 2006-2011 discusses prospects for the large developing market of Latin America. Importantly, the growth of pharmaceutical markets in Latin America has the potential to offset serious problems currently being experienced by your industry. The purpose of this visiongain report is to examine the prospects for the growth of pharmaceutical revenues in the developing economies of Latin America, at both regional and national level. |
|
 | Will the economic growth in new Asian markets allow you to offset global problems? With the Japan market slow and stagnant what other countries in the region offer you the greatest opportunities and how can you succeed in them. This report tells you.Asian Developing Markets for Pharmaceuticals, 2006-2011 delivers to you unique prospects for the largest developing pharmaceutical market - Asia. This report predicts that all the leading developing markets will exhibit strong growth from 2006-2011. Rapid economic growth and large, under-served populations will drive that expansion in pharmaceutical revenues. There will be significant growth in sales of both branded and generic drugs through increasing demand from both public and private healthcare sectors. |
|
 | "Outsourcing defines future of Euro Bioinformatics market" "Jump on bioinformatics bandwagon"These are just two newspaper headlines that appeared today. Managing your data is critical to your organisation. You already know that. But is your company doing it as effectively as it should? Find out by reading this brand new report.This report delivers answers on how you can benefit from the commercial prospects of bioinformatics, now. The ultimate goal of bioinformatics is to uncover the wealth of biological information hidden in the mass of data, to obtain a clearer insight into the fundamental biology of organisms. Is your Bioinformatic strategy working to the maximum level. These recent developments have a profound relevance to pharmaceutical development. |
|
 | More money is spent advertising alcohol than any other product. For some, it like gambling and cigerettes are pleasant distractions, yet for others they are the generators of unbearable cravings and the cause of considerable distress. For them their addition is a disease. According to a new report by visiongain - Anti-addiction Therapies, 2006-2011 - society is crying out for solutions. Which pharmaceutical companies are now aiming to be that cure? This report will tell you. |
|
 | The number of people suffering from some sort of allergy is on the rise and the demand for reliable treatments for allergic rhinitis and other allergic conditions is on the rise worldwide. The market is a mature one with a number of high profile patent losses in the near future and a strong OTC segment. Will there be a replacement for Zyrtec or Allegra in the near Future? What role will the new improved vaccines play in the next five years? Read visiongain’s new report to find out. |
|
 | In stark contrast to the rest of the pharmaceutical industry, the world market for biotech drugs is thriving. In 2005, biotech revenues reached $60bn and visiongain predicts that this will continue - YOU MUST BE PART OF THIS SUCCESS NOW. Having grown 16.5 per cent from 2004's revenues, double-digit growth of the market will continue to the end of the decade. You need to be aware of how you can succeed in this area. 1 report will tell you all you need to know. - Over 250+ pages- Over 150 tables and figures- Global revenues & growth rates for the leading biotech drugs- Company profiles of the leading biotech firms- A comprehensive analysis of the global market, 2005-2011- Revenue forecasts for the leading biotech drugs- Revenues into therapeutic area- Pipeline treatments- A geographic breakdown of the market- A Focus on biogenerics |
|
 | The purpose of this visiongain report is to examine the prospects for the growth of pharmaceutical revenues in the developing economies of Asia, Latin America and Eastern/Central Europe at both regional and national level. The growth of pharmaceutical markets in the developing nations has the potential to offset serious problems currently experienced by the global industry. The principal challenge is slow growth in North America, Western Europe and Japan. |
|
 | The asthma treatment market is a $15 billion market, driven by an increasing prevalence and yet without a treatment to cure this debilitating disease. All current drugs treat the symptoms but not the underlying cause. It is currently dominated by GSK with its $5.5 billion blockbuster, Advair/Seretide. However, this combination treatment is about to have its first real competition with Symbicort approved for the US market in July 2006. Combination drugs appear likely to dominate the mid-term forecast period as assessed by visiongain. |
|
 | The Contract Pharma market in 2005 was worth an estimated $57bn. Attitudes within the pharmaceutical industry are slowly changing and the use of strategic outsourcing is becoming an accepted practice. Specialised technologies and a global presence are becoming more important for a greater number of pharmaceutical companies. Even big pharma is increasingly using outsourcing to spread the risk of development and lower fixed costs. |
|
 | The purpose of this visiongain report is to examine the commercial prospects of online technologies in the pharmaceutical sector. In particular, this report examines the fast-growing fields of pharmaceutical eMarketing, eDetailing, ePrescribing and online drug sales. Online technological solutions have great potential to benefit - even revolutionise – the marketing efforts of drug companies. Visiongain predicts that all aspects of pharmaceutical eMarketing will exhibit steady growth from 2006-2011. Key technological solutions - such as Internet-enabled DTC promotion, eDetailing and ePrescribing - will drive that expansion. Sales of prescription drugs via the Internet will also be significant. |
|
 | At present ADRs are the sixth largest cause of death in the US. Drug safety is a huge issue facing the industry today and the risk is high with the possible loss of a key revenue producing drug coupled with potentially damaging litigation. The financial risk facing Merck on the withdrawal of Vioxx was considerably beyond the loss of its $2.5 bn yearly revenues. |
|
